DE69111205D1 - Stabilisierung von Calcitonin enthaltenden pharmazeutischen Verbindungen. - Google Patents

Stabilisierung von Calcitonin enthaltenden pharmazeutischen Verbindungen.

Info

Publication number
DE69111205D1
DE69111205D1 DE69111205T DE69111205T DE69111205D1 DE 69111205 D1 DE69111205 D1 DE 69111205D1 DE 69111205 T DE69111205 T DE 69111205T DE 69111205 T DE69111205 T DE 69111205T DE 69111205 D1 DE69111205 D1 DE 69111205D1
Authority
DE
Germany
Prior art keywords
stabilization
compounds containing
pharmaceutical compounds
acid
hct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69111205T
Other languages
English (en)
Other versions
DE69111205T2 (de
Inventor
Turdor Arvinte
Katherine Diana Ryman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909026882A external-priority patent/GB9026882D0/en
Priority claimed from GB919119048A external-priority patent/GB9119048D0/en
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Application granted granted Critical
Publication of DE69111205D1 publication Critical patent/DE69111205D1/de
Publication of DE69111205T2 publication Critical patent/DE69111205T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • External Artificial Organs (AREA)
DE69111205T 1990-12-11 1991-12-02 Stabilisierung von Calcitonin enthaltenden pharmazeutischen Verbindungen. Expired - Fee Related DE69111205T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909026882A GB9026882D0 (en) 1990-12-11 1990-12-11 Pharmaceutical compositions
GB919119048A GB9119048D0 (en) 1991-09-06 1991-09-06 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
DE69111205D1 true DE69111205D1 (de) 1995-08-17
DE69111205T2 DE69111205T2 (de) 1996-01-04

Family

ID=26298092

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69111205T Expired - Fee Related DE69111205T2 (de) 1990-12-11 1991-12-02 Stabilisierung von Calcitonin enthaltenden pharmazeutischen Verbindungen.

Country Status (16)

Country Link
EP (1) EP0490549B1 (de)
JP (1) JP3179538B2 (de)
KR (1) KR100253862B1 (de)
AT (1) ATE124869T1 (de)
AU (1) AU653371B2 (de)
CA (1) CA2057291C (de)
DE (1) DE69111205T2 (de)
DK (1) DK0490549T3 (de)
ES (1) ES2074236T3 (de)
HU (1) HU213204B (de)
IE (1) IE66398B1 (de)
IL (1) IL100239A (de)
MX (1) MX9102446A (de)
NZ (1) NZ240901A (de)
PH (1) PH30776A (de)
PT (1) PT99727B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5578323A (en) 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5397479A (en) * 1993-04-26 1995-03-14 International Remote Imaging Systems, Inc. Composition and method for enrichment of white blood cells from whole human blood
DE726075T1 (de) * 1995-02-08 1996-12-12 Therapicon Srl Nicht-inorganische pharmazeutische salzige Lösungen zur endonasale Verabreichung
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5750147A (en) 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
WO1997047288A1 (en) 1996-06-14 1997-12-18 Emisphere Technologies, Inc. Microencapsulated fragrances and method for preparation
US5726154A (en) * 1996-06-28 1998-03-10 University Of Utah Research Foundation Stabilization and oral delivery of calcitonin
KR100611559B1 (ko) * 1998-05-08 2007-04-25 동아제약주식회사 칼시토닌을 함유한 비강투여용 약제학적 조성물
ATE389414T1 (de) * 1999-09-08 2008-04-15 Chugai Pharmaceutical Co Ltd Stabile proteinlösung abgefüllt in einem behältnis aus hydrophobem harz und eine methode zur stabilisierung derselben
JP3498041B2 (ja) 2000-05-29 2004-02-16 科研製薬株式会社 プラルモレリン含有点鼻用製剤
AU2006259664A1 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
EP2471554A1 (de) * 2010-12-28 2012-07-04 Hexal AG Pharmazeutische Formulierung mit biopharmazeutischem Arzneimittel
SE536091C2 (sv) * 2011-04-14 2013-04-30 Pep Tonic Medical Ab Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter
SG11201903521XA (en) 2016-10-21 2019-05-30 Amgen Inc Pharmaceutical formulations and methods of making the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH657858A5 (de) * 1983-06-27 1986-09-30 Ciba Geigy Ag Substanz aus der gruppe der calcitonine.
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
MY102411A (en) * 1986-12-23 1992-06-17 Ciba Geigy Ag Nasal solutions
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
US5236704A (en) * 1988-01-28 1993-08-17 Sumitomo Pharmaceuticals Co., Ltd. Controlled release formulation
US5026825A (en) * 1988-09-08 1991-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Intranasal calcitonin formulations
JPH02174726A (ja) * 1988-12-23 1990-07-06 Toyo Jozo Co Ltd エルカトニン水溶液組成物の安定化法
JP2514249B2 (ja) * 1989-05-23 1996-07-10 帝人株式会社 安定化されたカルシトニン類医薬組成物

Also Published As

Publication number Publication date
KR100253862B1 (ko) 2000-09-01
ES2074236T3 (es) 1995-09-01
IE914294A1 (en) 1992-06-17
IE66398B1 (en) 1995-12-27
HU913887D0 (en) 1992-02-28
JP3179538B2 (ja) 2001-06-25
AU8889891A (en) 1992-06-18
KR920011516A (ko) 1992-07-24
CA2057291C (en) 2003-09-09
CA2057291A1 (en) 1992-06-12
IL100239A (en) 1996-06-18
HU213204B (en) 1997-03-28
HUT59832A (en) 1992-07-28
ATE124869T1 (de) 1995-07-15
JPH06340547A (ja) 1994-12-13
AU653371B2 (en) 1994-09-29
PH30776A (en) 1997-10-17
NZ240901A (en) 1993-03-26
IL100239A0 (en) 1992-09-06
EP0490549A1 (de) 1992-06-17
DE69111205T2 (de) 1996-01-04
EP0490549B1 (de) 1995-07-12
DK0490549T3 (da) 1995-08-21
MX9102446A (es) 1992-07-01
PT99727B (pt) 1999-05-31
PT99727A (pt) 1992-10-30

Similar Documents

Publication Publication Date Title
DE69111205T2 (de) Stabilisierung von Calcitonin enthaltenden pharmazeutischen Verbindungen.
DE69531314D1 (de) Verwendung von metallionen chelatoren zur stabilisierung von interferon-enthaltenden pharmazeutischen zubereitungen
DK358384D0 (da) Farmaceutiske midler til bekaempelse af diabetes mellitus
KR920019371A (ko) 안정화된 인자 ⅷ 제제
ATE76625T1 (de) Stabilisierte wasserstoffperoxidloesung.
ES2078332T3 (es) Disolucion de celulosa en agua y oxido-n de metilmorfolina-n.
DE69100436T2 (de) Kalzitonin enthaltende Emulsion zur nasalen Verabreichung.
DE3863859D1 (de) Stabile, injizierbare loesungen von salzen von vincristin.
DK534087A (da) Desinfektionsmiddel indeholdende en stabiliseret hydrogenperoxidoploesning til desinfektion af bloede kontaktlinser
NO875055L (no) Injiserbare, bruksferdige opploesninger inneholdende et antitumor-antracyklin glykosid.
DK443988D0 (da) Injektionspraeparat indeholdende modificeret tpa
FI902276A0 (fi) Menetelmä 8-N-(dietyyliaminoetyyli)rebekkamysiinin stabiilin vesiliuoksen valmistamiseksi
KR900009089A (ko) 알카토닌 수용액 조성물
ATE78402T1 (de) Waesserige loesungen von doxorubicin.
ATE135571T1 (de) Organogermaniumderivate enthaltende zubereitungen zur therapeutischen verwendung
IT1247752B (it) Composizioni farmaceutiche aventi come principio attivo calcitonina da somministrarsi per via intranasale.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS AG, BASEL, CH

8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC

8339 Ceased/non-payment of the annual fee